The Cepeda Framework: A Modular, Safety-First Preclinical Architecture for Testing Coordinated Multi-Hallmark Rejuvenation Hypotheses in Biological Aging

ABSTRACT Background The twelve hallmarks of aging as defined by López-Otín et al. (Cell, 2023) represent the primary, antagonistic, and integrative mechanisms driving biological aging. To our knowledge, no open-source preclinical framework has yet attempted to coordinate all 12 official hallmarks in a single modular, non-integrating, safety-gated design validated across tens of thousands of computational cycles. This manuscript presents The Cepeda Framework — a modular, safety-first preclinical research program designed to test whether coordinated partial rejuvenation strategies can be pursued in a falsifiable and systematically safety-constrained manner. Computational Development The framework was developed through 21,000 dual-validation simulation cycles — each simultaneously testing Efficacy (epigenetic reversal) and Safety (NANOG induction prevention) — executed by the Forward Thinking Communities Scientific Group over one year of intensive computational modeling. The program evolved through four distinct phases: from the original Genesis Framework single-hallmark concept (Cycles 1–5,000; FAILURE — 1:1:1 ratio unsafe), through stoichiometric ratio optimization (Cycles 5,001–12,000; PIVOT — 3:2:1 ratio locked), gate verification (Cycles 12,001–18,000; SUCCESS — dual-miRNA logic validated), and final 12-hallmark integration (Cycles 18,001–21,000; CONVERGENCE — Cepeda Framework finalized). Framework The Cepeda Framework integrates five regulatory principles — (I) stoichiometric 3:2:1 OCT4:SOX2:KLF4 polycistronic m1Ψ-saRNA; (II) 72-hour intrinsic saRNA pulse; (III) LEAD-7294 dual-miRNA logic gate (kill-switch + Let-7/L7Ae/Kt activation gate); (IV) NRF2/NAD+/paracrine microenvironmental co-treatment; (V) Genesis-TERT-01 transient hTERT telomere restoration — with five companion protocols (Rapamycin pulse, Metformin, AP39 H2S donor [HIGH-UNCERTAINTY; Tier 1A required], GGA/4-PBA proteostasis stack, and Akkermansia/synbiotic/butyrate dysbiosis correction). Together, these components map to all 12 official López-Otín 2023 hallmarks plus one Copenhagen 2022 candidate hallmark (RNA splicing dysregulation). Safety Nine parallel and sequential safety safeguards ensure no single-point failure produces uncontrolled reprogramming or sustained exposure, including the embedded LEAD-7294 miR-294 kill-switch (predicted t½ 5,000 copies/cell), the proactive Let-7/L7Ae/Kt activation gate, intrinsic saRNA transience, the 3:2:1 stoichiometric brake, and a predefined Acute Cytokine Response (ACR) monitoring protocol. All companion agents are clinically approved or have established in vitro/in vivo safety profiles. Status Theoretical preclinical framework. No wet-laboratory validation of the integrated protocol has been conducted. All quantitative predictions require experimental falsification. Validation proceeds through a five-tier modular preclinical roadmap beginning with aged human dermal fibroblasts. All simulation code and archives will be released under CC0 at or before preprint submission. Competing Interest Statement The authors declare no competing financial or non-financial interests. No payments or services were received from any third party in the past 36 months that could be perceived as influencing this work. All simulation code will be released under CC0 at or before public posting. Footnotes [email protected] · +1 484-721-1969 From the Genesis Framework to 12/12 Hallmark Proof — Computational Development Across 21,000 Dual-Validation Simulation Cycles, Five Regulatory Principles, Five Companion Protocols, and a Nine-Safeguard Defense-in-Depth Architecture Version 1.1 represents a comprehensive revision of the originally submitted Cepeda Framework manuscript. The following updates have been made: Framework Architecture: The five regulatory principles and five companion protocols have been expanded with full mechanistic detail, explicit delivery parameters, mouse dosing specifications, and primary literature citations for each component. Principle III (LEAD-7294 dual miRNA logic gate) has been clarified to distinguish the two architecturally distinct gate mechanisms: Gate A (miR-294 kill-switch, post-expression control) and Gate B (Let-7/L7Ae/Kt activation gate, pre-expression control). These are now correctly described as parallel rather than redundant safeguards. Companion C Uncertainty Flag: Companion C (AP39 H2S donor) has been reclassified as a HIGH-UNCERTAINTY component throughout the manuscript. Its validation basis is explicitly limited to endothelial cells (Latorre 2018, PMID 30048247, University of Exeter). Language has been updated in all sections to require mandatory Tier 1A independent HDF validation before inclusion in any full-stack protocol tier. Simulation Scale Documentation: The Official FTC Simulation Scale has been expanded to provide full phase-by-phase narrative documentation of all 21,000 dual-validation cycles, including the specific failure mode identified in Phase I, the stoichiometric discovery process across 15,000 combinations in Phase II, gate kinetics validation in Phase III, and the 12-hallmark integration rationale in Phase IV. Safety Architecture: The nine-safeguard stack has been expanded with explicit mechanism descriptions, active phase windows, and safeguard type classifications for each of the nine parallel and sequential safeguards. Validation Roadmap: The five-tier preclinical validation roadmap has been updated to include explicit Go and No-Go criteria for each tier, mandatory prerequisites between tiers, and clear language that no OSK saRNA is permitted in any experiment until Tier 1C gate validation passes. Reference List: The reference list has been updated to 34 verified publications. All citations have been confirmed as real publications with accurate bibliographic data. New references added include Barcena 2019, Depommier 2019, Plovier 2017, Jing 2025, Harrison 2009, Bitto 2016, and Moel 2025. Author Identifiers: ORCID iD (0009-0005-1400-5640) and bioRxiv MS ID (BIORXIV/2026/711859) added to manuscript header.